Challenges to the Translation of Genomic Information into Clinical Practice and Health Policy: Utilization, Preferences and Economic Value

Overview

Journal Curr Opin Mol Ther

Specialties Molecular Biology
Pharmacology

Date 2008 Jun 7

PMID 18535933

Citations 16

Authors

Kathryn A Phillips

Su-Ying Liang

Stephanie Van Bebber

Affiliations

Soon will be listed here.

Abstract

It is important to understand how knowledge of genomics can be translated from research into clinical practice and health policies. This review examines existing evidence on three key factors in the adoption of personalized medicine: utilization, preferences, and economic value, using two cancer examples: HER2/neu antigen testing and trastuzumab (Herceptin) treatment and genetic testing for Lynch syndrome. Our findings highlight areas in which additional research is required to build an evidence base addressing utilization of, preferences for, and the potential costs and benefits of personalized medicine. Major challenges include a lack of linked data, the need for relevant research frameworks and methodologies, and the clinical complexities of genomic-based diagnostics and treatment.

Citing Articles

A Comprehensive Review of Genetic Variations in Collagen-Encoding Genes and Their Implications in Intervertebral Disc Degeneration.

Goel S, Deshpande S, Dhaniwala N, Singh R, Suneja A, Jadawala V Cureus. 2024; 16(1):e52708.

PMID: 38384607 PMC: 10880043. DOI: 10.7759/cureus.52708.

Identification of potential key genes and functional role of CENPF in osteosarcoma using bioinformatics and experimental analysis.

Ma Y, Guo J, Li D, Cai X Exp Ther Med. 2021; 23(1):80.

PMID: 34934449 PMC: 8652394. DOI: 10.3892/etm.2021.11003.

Women's preferences for cancer risk management strategies in Lynch syndrome.

Sun C, Meyer L, Daniels M, Bodurka D, Nebgen D, Burton-Chase A Gynecol Oncol. 2019; 152(3):514-521.

PMID: 30876497 PMC: 6422049. DOI: 10.1016/j.ygyno.2018.11.027.

Assessing patient readiness for personalized genomic medicine.

Frost C, Andrulis I, Buys S, Hopper J, John E, Terry M J Community Genet. 2018; 10(1):109-120.

PMID: 29804257 PMC: 6325047. DOI: 10.1007/s12687-018-0365-5.

Oncologists' attitudes toward KRAS testing: a multisite study.

Harris J, Liljestrand P, Alexander G, Goddard K, Kauffman T, Kolevska T Cancer Med. 2014; 2(6):881-8.

PMID: 24403261 PMC: 3892392. DOI: 10.1002/cam4.135.

References

Bartlett J, Going J, Mallon E, Watters A, Reeves J, Stanton P . Evaluating HER2 amplification and overexpression in breast cancer. J Pathol. 2001; 195(4):422-8. DOI: 10.1002/path.971. View

Woelderink A, Ibarreta D, Hopkins M, Rodriguez-Cerezo E . The current clinical practice of pharmacogenetic testing in Europe: TPMT and HER2 as case studies. Pharmacogenomics J. 2005; 6(1):3-7. DOI: 10.1038/sj.tpj.6500341. View

Yaziji H, Goldstein L, Barry T, Werling R, Hwang H, Ellis G . HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004; 291(16):1972-7. DOI: 10.1001/jama.291.16.1972. View

Olsen K, Bojesen S, Gerdes A, Lindorff-Larsen K, Bernstein I . Cost-effectiveness of surveillance programs for families at high and moderate risk of hereditary non-polyposis colorectal cancer. Int J Technol Assess Health Care. 2007; 23(1):89-95. DOI: 10.1017/S0266462307051616. View

Phillips K, Van Bebber S . Measuring the value of pharmacogenomics. Nat Rev Drug Discov. 2005; 4(6):500-9. DOI: 10.1038/nrd1749. View

Braga S, Dal Lago L, Bernard C, Cardoso F, Piccart M . Use of trastuzumab for the treatment of early stage breast cancer. Expert Rev Anticancer Ther. 2006; 6(8):1153-64. DOI: 10.1586/14737140.6.8.1153. View

Guttmacher A, Collins F . Welcome to the genomic era. N Engl J Med. 2003; 349(10):996-8. DOI: 10.1056/NEJMe038132. View

Wolff A, Hammond M, Schwartz J, Hagerty K, Allred D, Cote R . American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2006; 25(1):118-45. DOI: 10.1200/JCO.2006.09.2775. View

Reyes C, Allen B, Terdiman J, Wilson L . Comparison of selection strategies for genetic testing of patients with hereditary nonpolyposis colorectal carcinoma: effectiveness and cost-effectiveness. Cancer. 2002; 95(9):1848-56. DOI: 10.1002/cncr.10910. View

10.

Norum J, Risberg T, Olsen J . A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis. Ann Oncol. 2005; 16(6):909-14. DOI: 10.1093/annonc/mdi188. View

11.

Freedman A, Wideroff L, Olson L, Davis W, Klabunde C, Srinath K . US physicians' attitudes toward genetic testing for cancer susceptibility. Am J Med Genet A. 2003; 120A(1):63-71. DOI: 10.1002/ajmg.a.10192. View

12.

Ginsburg G, Angrist M . The future may be closer than you think: a response from the Personalized Medicine Coalition to the Royal Society's report on personalized medicine. Per Med. 2018; 3(2):119-123. DOI: 10.2217/17410541.3.2.119. View

13.

Vadaparampil S, Wideroff L, Olson L, Viswanath K, Freedman A . Physician exposure to and attitudes toward advertisements for genetic tests for inherited cancer susceptibility. Am J Med Genet A. 2005; 135(1):41-6. DOI: 10.1002/ajmg.a.30681. View

14.

Bosompra K, Ashikaga T, Flynn B, Worden J, Solomon L . Psychosocial factors associated with the public's willingness to pay for genetic testing for cancer risk: a structural equations model. Health Educ Res. 2001; 16(2):157-72. DOI: 10.1093/her/16.2.157. View

15.

Todora H, Skinner C, Gidday L, Ivanovich J, Rawl S, Whelan A . Perceptions of genetic risk assessment and education among first-degree relatives of colorectal cancer patients and implications for physicians. Fam Pract. 2001; 18(4):367-72. DOI: 10.1093/fampra/18.4.367. View

16.

Dedes K, Szucs T, Imesch P, Fedier A, Fehr M, Fink D . Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial. Ann Oncol. 2007; 18(9):1493-9. DOI: 10.1093/annonc/mdm185. View

17.

Morelle M, Hasle E, Treilleux I, Michot J, Bachelot T, Penault-Llorca F . Cost-effectiveness analysis of strategies for HER2 testing of breast cancer patients in France. Int J Technol Assess Health Care. 2006; 22(3):396-401. DOI: 10.1017/s0266462306051300. View

18.

Codori A, Petersen G, Miglioretti D, Larkin E, Bushey M, Young C . Attitudes toward colon cancer gene testing: factors predicting test uptake. Cancer Epidemiol Biomarkers Prev. 1999; 8(4 Pt 2):345-51. View

19.

Elkin E, Weinstein M, Winer E, M Kuntz K, Schnitt S, Weeks J . HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol. 2004; 22(5):854-63. DOI: 10.1200/JCO.2004.04.158. View

20.

Ramsey S, Clarke L, Etzioni R, Higashi M, Berry K, Urban N . Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Intern Med. 2001; 135(8 Pt 1):577-88. DOI: 10.7326/0003-4819-135-8_part_1-200110160-00008. View